At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the development of therapies with novel monoclonal antibodies in multiple myeloma, including antibodies that target CD38, CS1 and PD-1.